| Literature DB >> 27120693 |
Rezaul M Karim1,2, Ernst Schönbrunn1,2.
Abstract
Selective inhibitors of bromodomain-containing protein 9 (BRD9) may have therapeutic potential in the treatment of human malignancies and inflammatory diseases. A selective small molecule inhibitor that is well tolerated and has proper pharmacokinetic properties is required to explore the function of BRD9 in diseases. BI-9564 (2) is a cell permeable and noncytotoxic BRD9 inhibitor provided to the scientific community to explore BRD9 biology and determine its potential as a drug target.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27120693 DOI： 10.1021/acs.jmedchem.6b00550
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446